- Teva Pharmaceuticals International GmbH and mAbxience have entered into a strategic licensing agreement for an oncology biosimilar candidate.
- The partnership is a significant step in mAbxience’s global expansion and aligns with Teva’s growth strategy to expand its biosimilar pipeline.
- The agreement will leverage mAbxience’s biosimilar development expertise and Teva’s regulatory and commercial capabilities to ensure broader patient access.
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications.
Under the terms of the licensing agreement, mAbxience will leverage its expertise in biosimilar development and its state-of-the-art, current Good Manufacturing Practice (cGMP)-approved facilities in Spain and Argentina, to develop and produce the biosimilar product. Teva, on the other hand, will lead the regulatory processes and commercialisation in the designated regions, to ensure access to a broader patient population.
“Teva is pleased to form this strategic alliance with mAbxience, who share our commitment to accelerate the delivery of impactful medicines to patients worldwide,” says Angus Grant, PhD, Executive Vice President of Business Development at Teva. “This collaboration reflects Teva’s ideal strategic partnership model to optimise development costs, mitigate risk and leverage our extensive commercial capabilities.”
“This agreement will assist healthcare systems in reducing costs, ensuring the provision of these vital cancer treatments to all patients who require them,” says Jurgen Van Broeck, Global Commercial Director of mAbxience.
